Rahul Sangani, MD
Pulmonary Disease · Gainesville, GANPI 1598063190
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Boehringer Ingelheim at 27.3% of the total. 2025 is the largest year on record at $760, 5.7 times the $133 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 44 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$319
- GSK$297
- Baxter Healthcare$83
- Sanofi$72
- Takeda Pharmaceuticals U.S.A., Inc.$71
- AstraZeneca$63
- plus $264 from 9 others
Across 7 payments — averaging $91,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$537K
- Hoffmann-la Roche Limited$102K
- Mallinckrodt Enterprises LLC$1K
What the payments were for
- Food & beverage$1,15499%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $319 |
| GSK | 16 | $297 |
| Baxter Healthcare | 3 | $83 |
| Sanofi | 2 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| AstraZeneca | 3 | $63 |
| Insmed, Inc. | 2 | $48 |
| AbbVie | 2 | $46 |
| Pulmonx Corporation | 1 | $35 |
| Verona Pharma, Inc. | 1 | $30 |
| Grifols USA, LLC | 1 | $26 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$249
How this compares
$1,168 in reported general payments places this provider in the 25th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 47 | $625,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $41,211 |
| Pirfenidone | 17 | $39,461 |
| Spiriva RespimatTiotropium Bromide | 31 | $20,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,233 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,974 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $8,919 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $6,976 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $6,828 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,931 |
| Arnuity ElliptaFluticasone Furoate | 15 | $3,082 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,876 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $1,987 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,604 |
| Montelukast Sodium | 93 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $319 | $654,80398 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $297 | $60,243111 claims |
| AstraZenecaSymbicort | $63 | $6,82829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Gainesville
- Vivek SambharaGainesville$417K
- Lawrence McDermottSavannah$963K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.